Sparstolonin B Based Pharmaceutical Agent to Treat Pathological Angiogensis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 9, 2014
app pub date -
Oct 17, 2013
filing date -
Apr 8, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Anti-angiogenesis methods and compositions are described. The anti-angiogenic effect is provided by application of sparstolonin B or a derivative thereof to endothelial cells. The sparstolonin B or derivative thereof can inhibit angiogenesis by targeting endothelial cell cycle progression, cell migration, and chemotaxis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully